PI
IMVT icon

PEAK6 Investments’s Immunovant IMVT Stock Holding History

PEAK6 Investments’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,500
Closed -$210K – 3942
2024
Q1 		$210K Buy
+6,500
New +$237K ﹤0.01% 3033

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

PEAK6 Investments's IMVT Position: Q3 2024 in Review

PEAK6 Investments reduced its Immunovant (IMVT) stake by 24% in Q3 2024, selling an estimated $147K and leaving 16,001 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

PEAK6 Investments first reported a position in IMVT in Q2 2022 and has held it in 6 quarters since. The position peaked at $741K in Q1 2024. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • PEAK6 Investments held 16,001 shares of Immunovant worth $456K as of Q3 2024.
  • PEAK6 Investments sold 4,986 Immunovant shares in Q3 2024, an estimated $147K.
  • Immunovant made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2375 holding.
  • PEAK6 Investments first reported a position in Immunovant in Q2 2022 and has held it in 6 quarters since.
  • PEAK6 Investments's Immunovant position peaked at $741K in Q1 2024.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.